Skip to content
Clinical Trials – home
GlaxoSmithKline Biologicals
Sponsor

GlaxoSmithKline Biologicals

Belgium Rue De L'Institut 89, 1330, Belgium

About the sponsor

Research activity centres on RSV vaccines for older adults, solid organ transplant recipients, and adults at increased risk of respiratory disease, with attention to immune response, safety, and vaccine co-administration.

  • RSVPreF3 OA
  • RSV-A and RSV-B immunity
  • Transplant recipients
  • Co-administration with pneumococcal and COVID-19 vaccines

The sponsor also studies persistence of protection and revaccination strategies in populations with heightened vulnerability to lower respiratory tract disease.

About Specializations

GlaxoSmithKline Biologicals runs clinical trials in conditions such as Influenza, Varicella, Respiratory syncytial virus infection, Influenza immunisation, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

30 clinical trials

Influenza+1

Recruiting

Study of the safety and immune response of gskvx000000077430 drug combination versus standard influenza vaccine in adults 18‑64 years

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:GlaxoSmithKline Biologicals

Influenza+1

Recruiting

Efficacy and safety of the investigational mRNA influenza vaccine gskvx000000077430 (drug combination) in adults ≥ 65 years

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years · Healthy volunteers
  • Substances:INFLUENZA A VIRUS, A/CROATIA/10136RV/2023 (H3N2) LIKE STRAIN X-425A, INACTIVATED
  • Sponsor:GlaxoSmithKline Biologicals

Dementia

Recruiting

Evaluating the effect of recombinant varicella zoster virus glycoprotein E on the risk of dementia in adults aged 76 years and older

Registered drug
Countries:FinlandFinland
  • Participants:65+ years · Healthy volunteers
  • Substances:Recombinant Varicella Zoster Virus Glycoprotein E
  • Sponsor:GlaxoSmithKline Biologicals

Study of RSV vaccine immune response persistence and revaccination safety in adult lung and kidney transplant recipients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Varicella

Recruiting

Study of new chickenpox vaccine and measles-mumps-rubella vaccine given by intramuscular injection in healthy children aged 12 to 15 months

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Varicella

Recruiting

Study on the Immune Response and Safety of a New Varicella Vaccine (GSKVX000000025896) Compared to Varicella Virus Oka/Merck Strain in Healthy Children Aged 12-15 Months

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Varicella+5

Not yet recruiting

Immune response and safety of investigational MMRV vaccine (GSKVX000000025896) drug combination compared with standard MMRV vaccine in healthy children 15 months to 6 years

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Varicella

Not yet recruiting

Study on the Immune Response and Safety of a Second Dose of Investigational Varicella Vaccine (GSKVX000000025896) Compared to Varicella Virus Oka/Merck Strain in Healthy Children

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Varicella immunisation+1

Not yet recruiting

Study on Immune Response and Safety of Measles, Mumps, Rubella, and Varicella Vaccine in Healthy Children Aged 4 to 6 Years

Registered drugNo placebo
Countries:LatviaLatvia
  • Participants:0–17 years · Healthy volunteers
  • Substances:GSKVX000000025896
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Safety and Immune Response of RSVPreF3 OA Vaccine with PCV20 in Adults Aged 60 and Older with RSV Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Pneumococcal Polysaccharide Serotype 1 Conjugated To Crm197 Adsorbed On Aluminium Phosphate
  • Sponsor:GlaxoSmithKline Biologicals
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Study on the Immune Response and Safety of RSVPreF3 OA Vaccine in Adults Aged 60+ with Respiratory Syncytial Virus Infections

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Respiratory Syncytial Virus, Glycoprotein F, Recombinant, Stabilised In The Pre-Fusion Conformation, Adjuvanted With As01E
  • Sponsor:GlaxoSmithKline Biologicals

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.